GlassScriptPhysician profile
Todd Ruth
NPI 1437569779
$20,183.09
in general payments reported to CMS, 2019-2025
52 companies · $1,596 in 2025
The $1,596 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,778 · 2020: $2,582 · 2021: $4,436 · 2022: $6,225 · 2023: $2,165 · 2024: $1,400 · 2025: $1,596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,161.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $11,770.70 | 2019-2024 | Senza |
| Abbvie INC. | $1,152.27 | 2021-2023 | Ubrelvy, Qulipta |
| Abbott Laboratories | $992.90 | 2019-2025 | Eterna, Proclaim |
| Globus Medical, INC. | $959.52 | 2025 | Senza, Vyrsa V1, Vyrsa V1 |
| Vertos Medical, INC. | $728.05 | 2020-2024 | Mild Device Kit |
| Medtronic, INC. | $508.12 | 2021-2024 | Intellis Adaptivestim, Kyphon Express II Kyphopak Tray, Atakr II |
| Boston Scientific Corporation | $455.84 | 2019-2025 | Wavewriter Alpha Prime 16, Intracept, Superion Indirect Decompression System |
| Collegium Pharmaceutical, INC. | $382.45 | 2019-2025 | Xtampza, Belbuca |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $348.55 | 2021-2025 | Relistor |
| Teva Pharmaceuticals USA, INC. | $232.57 | 2019-2021 | |
| Electronic Waveform Lab, INC. | $199.52 | 2019-2025 | |
| Saluda Medical Americas, INC. | $181.54 | 2024-2025 | Evoke |
| Medtronic USA, INC. | $178.03 | 2020 | |
| Grt US Holding, INC. | $160.07 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $156.01 | 2022 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Ruth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.